Pharmacy & Therapeutics - September 2008 - (Page 510)

EDITORIAL continued from page 503 MEDICATION ERRORS continued from page 504 In my view, it’s a good management practice to evaluate literature from fields outside our own. Not everything is directly applicable, but I am confident that we have a lot to learn from our colleagues in different industries. I hope that becoming familiar with some of these business trends will be helpful to your P&T committee. As always, I am interested in your views. You can reach me at my e-mail address, david.nash@jefferson.edu. Be sure to also visit my blog at http://depar tmentofhealthpolicy. blogspot.com. REFERENCE 1. Manyika JM, Roberts RP, Sprague KL. Eight business technology trends to watch. McKinsey Q 2008;1:61–71. I from the pharmaceutical industry that formularies inhibit prescribers’ knowledge of their products and restrict the freedom to use medications approved by the Food and Drug Administration. The lack of training about using formularies as a powerful patient safety/quality tool—rather than a restrictive cost-containment strategy—during medical and pharmacy training also hinders progress and allows biased, negative feelings about formularies to be reinforced. Sadly, one fact becomes clear from this survey: tapping into the enormous potential of formularies will require a marathon in health care, not a sprint. Holding frank discussions about the formulary myths might be one giant step toward providing optimal health care for patients. Focusing attention on the basic purpose and theory of formularies by medical and nursing schools, the research community, and funding agencies may also help to identify the most appropriate role of drug formularies in society today. REFERENCE 1. Rucker TD, Schiff G. Drug formularies: Myths-in-formation. Med Care 1990;28: 928–942. Reprinted in Hosp Pharm 1991; 26:507–514. The reports described in this column were received through the USP–ISMP Medication Errors Reporting Program (MERP). Errors, close calls, or hazardous conditions may be reported on the ISMP (www. ismp.org) or the USP (www.usp.org) Web site or communicated directly to ISMP by calling 1-800-FAILSAFE or via e-mail at ismpinfo@ismp.org. I COMING SOON TO P&T EDITORIAL: Moody’s Musings David B. Nash, MD, MBA DRUG FORECAST: Alvimopan: Review of a Newly Approved, Novel Peripherally Acting mu-Opioid Receptor (PAM-OR) Antagonist Goldina Ikezuagu Erowele, PharmD HEALTH CARE AND LAW: Why Is Health Care Regulation So Complex? Robert I. Field, JD, MPH, PhD FEATURE ARTICLE: Medical Management of Parkinson’s Disease Marvin M. Goldenberg, PhD, RPh, MS CORRECTION In the print edition of the August 2008 issue of P&T, in the article entitled “The Pharmacological Management of Migraine,” a sentence in column 2, paragraph 4, on page 483 contained the wrong brand name for a drug. The sentence said: “The triptans, including sumatriptan (Sutent, Pfizer), rizatriptan (Maxalt, Merck), and zolmitriptan (Zomig, AstraZeneca), were reported to be safe but not superior to placebo.” The sentence should read as follows: “The triptans, including sumatriptan (Imitrex, GlaxoSmithKline), rizatriptan (Maxalt, Merck), and zolmitriptan (Zomig, AstraZeneca), were reported to be safe but not superior to placebo.” The error has been corrected in the online and digital versions of the journal. 510 P&T® • September 2008 • Vol. 33 No. 9 http://departmentofhealthpolicy.blogspot.com http://departmentofhealthpolicy.blogspot.com http://www.ismp.org http://www.usp.org

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - September 2008

Pharmacy & Therapeutics - September 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/New Medical Devices Drug Forecast Effect of Prescription Copays on Adherence and Treatment Failure with Oral Antidiabetic Medications Vaccine Declinations Present New Challenges for Public Health Universal Health Care in America Digestive Disease Week and American Diabetes Association Pharmaceutical Approval Update

Pharmacy & Therapeutics - September 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.